Press Release
Printer-Friendly
News |
SAS unveils SAS® for Patient Safety at DIA 44th Annual MeetingA next-generation safety solution to address new regulations, signal detection and pharmacovigilanceCARY, NC (June 23, 2008) – SAS, the leader in business intelligence, today debuted SAS® for Patient Safety at the DIA 44th Annual Meeting in Boston, MA. SAS for Patient Safety is a next-generation safety solution that will help life sciences research companies address new regulated safety guidance and provide the most advanced analytics available for signal detection and pharmacovigilance. SAS for Patient Safety comes at a critical juncture. Regulatory authorities, patients, healthcare professionals, government officials and the media are increasing their scrutiny of life sciences research companies based on continuing, high-profile patient safety issues. SAS for Patient Safety integrates standard safety analyses that address new FDA guidances, emerging and established CDISC standards, and advanced signal detection analytics. The result is a comprehensive safety solution that adapts to changing regulations and emerging analytical techniques. “Merial is a long-time SAS user and collaborated with SAS to provide a unique safety solution customized for post-marketing surveillance,” said Kari Blaho-Owens head of global pharmacovigilance at Merial Limited. “The signal detection algorithms provide Merial with unique capabilities to understand the safety profiles of the therapies they have brought to market.” Using SAS for Patient Safety, life sciences companies will be able to take a more comprehensive and proactive approach to pre- and post-market safety concerns, increasing their ability to rapidly and effectively respond to safety inquiries with the most complete scientific information available. Accurate safety signal identification and evaluation is critical to the welfare of patients and SAS for Patient Safety leverages the industry’s most advanced analytics in conjunction with newly standardized safety reporting guidance from FDA so that both drug companies and regulators share a common, consistent view of available safety-related information and interpretation. “The life sciences industry is rapidly evolving around patient safety,” said Alan Louie, at Health Industry Insights, an IDC company. “Consumer and regulatory pressure to improve the safety of marketed therapies are driving companies to adopt a more comprehensive, analytically-driven view of a therapy’s complete lifecycle safety profile. SAS is now providing a way to get these insights by bringing together existing safety systems and data into a standardized environment powered by some of the most advanced analytics available.” Visual business intelligenceSAS has moved beyond simple tabulations of p-values and frequencies. Sophisticated data visualization capabilities enable researchers to explore and understand patient safety like never before. “The critical nature of patient safety demands a rigorous approach. SAS for Patient Safety combines data standardization, regulatory-driven reporting and the most advanced analytics available for signal detection and pharmacovigilance,” said Jason Burke, worldwide director of health and life sciences at SAS. “The breadth and depth of the underlying solution architecture makes SAS for Patient Safety a powerful ally in helping life sciences companies fully understand the safety profile of their therapies.” SAS for Patient Safety includes all the standard reports outlined in the FDA Good Review Practices, plus a signal detection and analysis accelerator. An integrated suite of solutions for Life SciencesSAS understands that each stage of bringing a new therapy to market has unique needs. SAS Solutions for Life Sciences distinctly address these needs through a portfolio of integrated solutions that drive efficiencies and deeper insights throughout every stage of a therapy’s lifecycle: from discovery, through development, commercialization and beyond. Globally recognized as the industry leader in analytics, the de facto standard for clinical data analysis, and the choice of 100% percent of the Fortune 500 life sciences companies, SAS assures accurate, comprehensive, and reliable analysis of life sciences research and business data. Pharmaceutical, biotechnology, medical device and contract research customers worldwide trust SAS to support their businesses, including AstraZeneca, Eli Lilly and Company, Genaissance Pharmaceuticals, ImpactRx, IMS Health, OSI Pharmaceuticals Inc., Sanofi-Aventis, Santarus, Inc, Solvay Pharmaceuticals, Speedel Experimenta Ltd, Synteract and Vertex Pharmaceuticals.
SAS is the leader in business intelligence and analytical software and services. Customers at more than 44,000 sites use SAS software to improve performance through insight from data, resulting in faster, more accurate business decisions; more profitable relationships with customers and suppliers; compliance with governmental regulations; research breakthroughs; and better products and processes. Only SAS offers leading data integration, storage, analytics and business intelligence applications within a comprehensive enterprise intelligence platform. Since 1976, SAS has been giving customers around the world
The Power to Know®
.
|
Editorial Contacts:
Visit the SAS Press Center for more information. |